| Angela E Eggebrecht, AUDIOLOGIST | |
|
421 Camelot Dr, Fond Du Lac, WI 54935-8335 | |
| (920) 926-8460 | |
| Not Available |
| Full Name | Angela E Eggebrecht |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 14 Years |
| Location | 421 Camelot Dr, Fond Du Lac, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346554987 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 552 (Wisconsin) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Agnesian Healthcare Inc | 1658289624 | 319 |
News Archive
To better understand why people without cognitive symptoms are at risk of falling, first author Audrey Kelemen, a graduate student in Stark's lab, and colleagues followed 83 people over age 65 for a year.
Building on data from The Cancer Genome Atlas project, a multi-institutional team of scientists has completed the first large-scale "proteogenomic" study of breast cancer, linking DNA mutations to protein signaling and helping pinpoint the genes that drive cancer.
Working in a more intellectually challenging job is associated with better memory and other aspects of cognitive functioning, reports a study in the June Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine.
Cinterion Wireless Modules, the global leader in cellular machine-to-machine (M2M) communication modules, and Diabetech, the leader in patient-centric health care programs, today announced their collaboration on the fourth generation GlucoMON® platform, the world's easiest-to-use wireless diabetes management system designed to help the over 220 million people worldwide struggling to manage the global diabetes and pre-diabetes pandemic.
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.
› Verified 5 days ago
| Provider Name | Agnesian Healthcare Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1346228541 PECOS PAC ID: 1658289624 Enrollment ID: O20031104000263 |
News Archive
To better understand why people without cognitive symptoms are at risk of falling, first author Audrey Kelemen, a graduate student in Stark's lab, and colleagues followed 83 people over age 65 for a year.
Building on data from The Cancer Genome Atlas project, a multi-institutional team of scientists has completed the first large-scale "proteogenomic" study of breast cancer, linking DNA mutations to protein signaling and helping pinpoint the genes that drive cancer.
Working in a more intellectually challenging job is associated with better memory and other aspects of cognitive functioning, reports a study in the June Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine.
Cinterion Wireless Modules, the global leader in cellular machine-to-machine (M2M) communication modules, and Diabetech, the leader in patient-centric health care programs, today announced their collaboration on the fourth generation GlucoMON® platform, the world's easiest-to-use wireless diabetes management system designed to help the over 220 million people worldwide struggling to manage the global diabetes and pre-diabetes pandemic.
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Angela E Eggebrecht, AUDIOLOGIST 420 E Division St, Fond Du Lac, WI 54935-4560 Ph: (920) 926-8340 | Angela E Eggebrecht, AUDIOLOGIST 421 Camelot Dr, Fond Du Lac, WI 54935-8335 Ph: (920) 926-8460 |
News Archive
To better understand why people without cognitive symptoms are at risk of falling, first author Audrey Kelemen, a graduate student in Stark's lab, and colleagues followed 83 people over age 65 for a year.
Building on data from The Cancer Genome Atlas project, a multi-institutional team of scientists has completed the first large-scale "proteogenomic" study of breast cancer, linking DNA mutations to protein signaling and helping pinpoint the genes that drive cancer.
Working in a more intellectually challenging job is associated with better memory and other aspects of cognitive functioning, reports a study in the June Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine.
Cinterion Wireless Modules, the global leader in cellular machine-to-machine (M2M) communication modules, and Diabetech, the leader in patient-centric health care programs, today announced their collaboration on the fourth generation GlucoMON® platform, the world's easiest-to-use wireless diabetes management system designed to help the over 220 million people worldwide struggling to manage the global diabetes and pre-diabetes pandemic.
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.
› Verified 5 days ago
Elizabeth A Gorman, MS CCC-A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 421 Camelot Dr, Fond Du Lac, WI 54935 Phone: 920-926-8460 | |
Nicole K Auxier, MA CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 421 Camelot Dr, Fond Du Lac, WI 54935 Phone: 920-926-8460 | |
Catherine L Conely, CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 210 Wisconsin American Dr, Fond Du Lac, WI 54935 Phone: 920-907-7000 | |
Kristin A Nytes, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 210 Wisconsin American Dr, Fond Du Lac, WI 54935 Phone: 920-907-7000 | |
Katherine A. Tobin, AU.D., CCC/A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 481 E Division St, Suite 900, Fond Du Lac, WI 54935 Phone: 920-926-1288 | |
Abby E Friske, AUD, CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 421 Camelot Dr, Fond Du Lac, WI 54935 Phone: 920-926-8460 |